activins has been researched along with Benign Neoplasms in 40 studies
Activins: Activins are produced in the pituitary, gonads, and other tissues. By acting locally, they stimulate pituitary FSH secretion and have diverse effects on cell differentiation and embryonic development. Activins are glycoproteins that are hetero- or homodimers of INHIBIN-BETA SUBUNITS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Baicalin is a natural flavonoid that can reduce skeletal muscle atrophy in animal models of cancer cachexia by inhibiting NF-κB." | 3.83 | Baicalin supplementation reduces serum biomarkers of skeletal muscle wasting and may protect against lean body mass reduction in cancer patients: Results from a pilot open-label study. ( Bertona, M; Emanuele, E; Fiuza-Luces, C; Lucia, A; Morales, JS; Pareja-Galeano, H; Sanchis-Gomar, F, 2016) |
| "It has been shown that cancers use the mechanisms of wound healing to promote their own growth." | 2.66 | Wound Repair, Scar Formation, and Cancer: Converging on Activin. ( Cangkrama, M; Werner, S; Wietecha, M, 2020) |
| "However, the use of ESAs in anemic cancer patients is associated with reduced survival time and time to progression." | 2.52 | Experimental and investigational therapies for chemotherapy-induced anemia. ( Castelli, G; Elvira, P; Testa, U, 2015) |
| "Cancer cachexia is characterized by a significant reduction in body weight resulting predominantly from loss of adipose tissue and skeletal muscle." | 2.48 | Cancer cachexia: mediators, signaling, and metabolic pathways. ( Fearon, KC; Glass, DJ; Guttridge, DC, 2012) |
| "Activins have been shown to mediate their signals through type I and type II serine/threonine kinase receptors." | 2.39 | Transgenic models to study the roles of inhibins and activins in reproduction, oncogenesis, and development. ( Behringer, RR; Coerver, KA; Finegold, MJ; Kumar, TR; Lau, AL; Matzuk, MM; Shou, W, 1996) |
| "In older patients with cancer, high serum concentrations of activin A and myostatin were predictive of poor OS." | 1.51 | Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors. ( Baek, JY; Hong, DS; Hong, S; Hong, YS; Hwang, IG; Jang, JS; Kim, HJ; Kim, JH; Kim, JW; Kim, SH; Kim, TY; Lee, JH; Shin, SH; Sun, S; Woo, IS, 2019) |
| "During tumorigenesis, cancer cells use two different approaches to evade this barrier, either downregulating activin B and/or downregulating ALK7." | 1.51 | ALK7 Signaling Manifests a Homeostatic Tissue Barrier That Is Abrogated during Tumorigenesis and Metastasis. ( Hanahan, D; Marinoni, I; Michael, IP; Perren, A; Saghafinia, S; Tichet, M; Zangger, N, 2019) |
| "Patients with advanced solid tumors were enrolled in 8 dose cohorts ranging from 0." | 1.51 | First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors. ( Cadoo, KA; Cangemi, NA; Haqq, CM; Hyman, DM; Liu, JF; Makker, V; Navarro, WH; Rasco, DW; Tao, JJ, 2019) |
| "Patients with colorectal or lung cancer were prospectively enrolled at the time of diagnosis or relapse between January 2012 and March 2014." | 1.46 | Circulating Activin A predicts survival in cancer patients. ( de Barsy, M; Gruson, D; Lause, P; Loumaye, A; Nachit, M; Thissen, JP; Trefois, P; van Maanen, A, 2017) |
| "Cachexia is a life-threatening wasting syndrome lacking effective treatment, which arises in many cancer patients." | 1.43 | Differential Effects of IL6 and Activin A in the Development of Cancer-Associated Cachexia. ( Chen, JL; Colgan, TD; Gregorevic, P; Hagg, A; Harrison, CA; Qian, H; Walton, KL; Watt, MJ, 2016) |
| "Notably, cancer associated fibroblasts (CAF) and cancer cells were resistant to TGFβ mediated suppression of CD248." | 1.40 | TGFβ-mediated suppression of CD248 in non-cancer cells via canonical Smad-dependent signaling pathways is uncoupled in cancer cells. ( Calvo, F; Conway, EM; Lei, V; O'Byrne, AM; Suresh Babu, S; Valdez, Y; Xu, A, 2014) |
| "The study of cancer cell dormancy is severely hampered by the lack of biological samples so that the mechanisms that regulate cell dormancy have not been extensively explored." | 1.37 | A dormant state modulated by osmotic pressure controls clonogenicity of prostate cancer cells. ( Dautry, F; Havard, M; Tchénio, T, 2011) |
| "Muscle wasting and cachexia have long been postulated to be key determinants of cancer-related death, but there has been no direct experimental evidence to substantiate this hypothesis." | 1.36 | Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. ( Boone, T; Chen, Q; Goldberg, AL; Han, HQ; Jiao, Q; Kwak, KS; Lacey, DL; Lu, J; Rosenfeld, R; Simonet, WS; Song, Y; Wang, JL; Zhou, X, 2010) |
| "In breast and cervical cancer cells, activin-A resulted in telomerase activity in a concentration-dependent manner." | 1.35 | Activin inhibits telomerase activity in cancer. ( Jiang, FX; Katik, I; Li, H; Liu, JP; Mackenzie-Kludas, C; Nicholls, C; Zhou, S, 2009) |
| " As a result of this extraction procedure, the dose-response curve of serum extract was parallel to the standard curve and a single immunoreactive (ir-) peak was demonstrated on gel chromatographic analysis with constant recovery rates over 80%." | 1.29 | Serum immunoreactive activin A levels in normal subjects and patients with various diseases. ( Harada, K; Saito, S; Sakamoto, Y; Shintani, Y; Shitsukawa, K; Wakatsuki, M, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.00) | 18.2507 |
| 2000's | 10 (25.00) | 29.6817 |
| 2010's | 23 (57.50) | 24.3611 |
| 2020's | 5 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Hagg, A | 2 |
| O'Shea, E | 1 |
| Harrison, CA | 3 |
| Walton, KL | 2 |
| Wang, X | 1 |
| Song, C | 1 |
| Ye, Y | 1 |
| Gu, Y | 1 |
| Li, X | 1 |
| Chen, P | 1 |
| Leng, D | 1 |
| Xiao, J | 1 |
| Wu, H | 1 |
| Xie, S | 1 |
| Liu, W | 1 |
| Zhao, Q | 1 |
| Chen, D | 1 |
| Chen, X | 1 |
| Wu, Q | 1 |
| Chen, G | 1 |
| Zhang, W | 1 |
| Morianos, I | 1 |
| Papadopoulou, G | 1 |
| Semitekolou, M | 1 |
| Xanthou, G | 1 |
| Ries, A | 1 |
| Schelch, K | 1 |
| Falch, D | 1 |
| Pany, L | 1 |
| Hoda, MA | 1 |
| Grusch, M | 1 |
| Cao, Z | 1 |
| Jose, I | 1 |
| Glab, J | 1 |
| Puthalakath, H | 1 |
| Osellame, LD | 1 |
| Hoogenraad, NJ | 1 |
| Cangkrama, M | 1 |
| Wietecha, M | 1 |
| Werner, S | 2 |
| Loumaye, A | 2 |
| de Barsy, M | 1 |
| Nachit, M | 1 |
| Lause, P | 1 |
| van Maanen, A | 1 |
| Trefois, P | 1 |
| Gruson, D | 1 |
| Thissen, JP | 2 |
| Miller, DSJ | 1 |
| Bloxham, RD | 1 |
| Jiang, M | 1 |
| Gori, I | 1 |
| Saunders, RE | 1 |
| Das, D | 1 |
| Chakravarty, P | 1 |
| Howell, M | 1 |
| Hill, CS | 1 |
| Kim, SH | 1 |
| Kim, JW | 1 |
| Hwang, IG | 1 |
| Jang, JS | 1 |
| Hong, S | 1 |
| Kim, TY | 1 |
| Baek, JY | 1 |
| Shin, SH | 1 |
| Sun, S | 1 |
| Hong, DS | 1 |
| Kim, HJ | 1 |
| Hong, YS | 1 |
| Woo, IS | 1 |
| Lee, JH | 1 |
| Kim, JH | 1 |
| Cui, X | 2 |
| Shang, S | 1 |
| Lv, X | 1 |
| Zhao, J | 1 |
| Qi, Y | 1 |
| Liu, Z | 1 |
| Michael, IP | 1 |
| Saghafinia, S | 1 |
| Tichet, M | 1 |
| Zangger, N | 1 |
| Marinoni, I | 1 |
| Perren, A | 1 |
| Hanahan, D | 1 |
| Tao, JJ | 1 |
| Cangemi, NA | 1 |
| Makker, V | 1 |
| Cadoo, KA | 1 |
| Liu, JF | 1 |
| Rasco, DW | 1 |
| Navarro, WH | 1 |
| Haqq, CM | 1 |
| Hyman, DM | 1 |
| Suresh Babu, S | 1 |
| Valdez, Y | 1 |
| Xu, A | 1 |
| O'Byrne, AM | 1 |
| Calvo, F | 1 |
| Lei, V | 1 |
| Conway, EM | 1 |
| Testa, U | 1 |
| Castelli, G | 1 |
| Elvira, P | 1 |
| Chen, JL | 1 |
| Qian, H | 1 |
| Colgan, TD | 1 |
| Watt, MJ | 1 |
| Gregorevic, P | 1 |
| Emanuele, E | 1 |
| Bertona, M | 1 |
| Pareja-Galeano, H | 1 |
| Fiuza-Luces, C | 1 |
| Morales, JS | 1 |
| Sanchis-Gomar, F | 1 |
| Lucia, A | 1 |
| Chen, W | 1 |
| Ten Dijke, P | 1 |
| Pickup, MW | 1 |
| Owens, P | 1 |
| Moses, HL | 1 |
| Katik, I | 1 |
| Mackenzie-Kludas, C | 1 |
| Nicholls, C | 1 |
| Jiang, FX | 1 |
| Zhou, S | 1 |
| Li, H | 1 |
| Liu, JP | 1 |
| Katoh, M | 2 |
| Zhou, X | 1 |
| Wang, JL | 1 |
| Lu, J | 1 |
| Song, Y | 1 |
| Kwak, KS | 1 |
| Jiao, Q | 1 |
| Rosenfeld, R | 1 |
| Chen, Q | 1 |
| Boone, T | 1 |
| Simonet, WS | 1 |
| Lacey, DL | 1 |
| Goldberg, AL | 1 |
| Han, HQ | 1 |
| Vanchieri, C | 1 |
| Mathew, SJ | 1 |
| de Kretser, D | 1 |
| Henrik-Heldin, C | 1 |
| Havard, M | 1 |
| Dautry, F | 1 |
| Tchénio, T | 1 |
| Caja, L | 1 |
| Kahata, K | 1 |
| Moustakas, A | 1 |
| Fearon, KC | 1 |
| Glass, DJ | 1 |
| Guttridge, DC | 1 |
| Antsiferova, M | 1 |
| Shen, MM | 1 |
| Naumnik, B | 1 |
| Borawski, J | 1 |
| Myśliwiec, M | 1 |
| Gray, PC | 1 |
| Vale, WW | 1 |
| Robertson, DM | 2 |
| Koinuma, D | 1 |
| Imamura, T | 1 |
| Miyazono, K | 1 |
| Chen, YG | 1 |
| Wang, Q | 1 |
| Lin, SL | 1 |
| Chang, CD | 1 |
| Chuang, J | 1 |
| Chung, J | 1 |
| Ying, SY | 1 |
| Tsuchida, K | 1 |
| Nakatani, M | 1 |
| Uezumi, A | 1 |
| Murakami, T | 1 |
| Matzuk, MM | 1 |
| Kumar, TR | 1 |
| Shou, W | 1 |
| Coerver, KA | 1 |
| Lau, AL | 1 |
| Behringer, RR | 1 |
| Finegold, MJ | 1 |
| Harada, K | 1 |
| Shintani, Y | 1 |
| Sakamoto, Y | 1 |
| Wakatsuki, M | 1 |
| Shitsukawa, K | 1 |
| Saito, S | 1 |
| Bernard, DJ | 1 |
| Chapman, SC | 1 |
| Woodruff, TK | 1 |
| Phillips, DJ | 1 |
| Risbridger, GP | 1 |
| Schmitt, JF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label Multiple Ascending Dose Phase 1/1B Pharmacokinetic and Pharmacodynamic Study of STM 434, an Activin Type 2B Receptor Fc Fusion, Alone and in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumor[NCT02262455] | Phase 1 | 32 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| The Investigation of the Mechanism of Cachexia Occurrence for Patients With Gastrointestinal Cancer[NCT04594863] | 100 participants (Anticipated) | Observational | 2020-11-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
20 reviews available for activins and Benign Neoplasms
| Article | Year |
|---|---|
Activin-A in the regulation of immunity in health and disease.
Topics: Active Transport, Cell Nucleus; Activins; Animals; Autoimmune Diseases; Cell Nucleus; Dendritic Cell | 2019 |
Activin A: an emerging target for improving cancer treatment?
Topics: Activins; Animals; Biomarkers, Tumor; Cachexia; Drug Resistance, Neoplasm; Humans; Molecular Targete | 2020 |
Wound Repair, Scar Formation, and Cancer: Converging on Activin.
Topics: Activins; Animals; Biomarkers; Cicatrix; Disease Susceptibility; Fibroblasts; Humans; Neoplasms; Wou | 2020 |
Perspectives of small molecule inhibitors of activin receptor‑like kinase in anti‑tumor treatment and stem cell differentiation (Review).
Topics: Activin Receptors; Activins; Animals; Cell Differentiation; Humans; Mesenchymal Stem Cells; Neoplasm | 2019 |
[Role of Activin A and Myostatin in cancer cachexia].
Topics: Activins; Animals; Cachexia; Humans; Mice; Mice, Knockout; Myostatin; Neoplasms | 2013 |
Experimental and investigational therapies for chemotherapy-induced anemia.
Topics: Activins; Anemia; Animals; Antineoplastic Agents; Disease Progression; Drug Design; Drugs, Investiga | 2015 |
Immunoregulation by members of the TGFβ superfamily.
Topics: Activins; Animals; Bone Morphogenetic Proteins; Gene Expression Regulation; Homeostasis; Humans; Imm | 2016 |
TGF-β, Bone Morphogenetic Protein, and Activin Signaling and the Tumor Microenvironment.
Topics: Activins; Animals; Bone Morphogenetic Proteins; Humans; Neoplasms; Signal Transduction; Transforming | 2017 |
Context-dependent action of transforming growth factor β family members on normal and cancer stem cells.
Topics: Activins; Adult; Adult Stem Cells; Animals; Antineoplastic Agents; Bone Morphogenetic Proteins; Dise | 2012 |
Cancer cachexia: mediators, signaling, and metabolic pathways.
Topics: Activins; Cachexia; Humans; Interleukin-6; Lipolysis; Metabolic Networks and Pathways; Models, Biolo | 2012 |
The bright and the dark sides of activin in wound healing and cancer.
Topics: Activins; Animals; Cicatrix; Fibrosis; Humans; Neoplasms; Signal Transduction; Wound Healing | 2012 |
Decrypting the role of Cripto in tumorigenesis.
Topics: Activins; Amino Acid Motifs; Animals; Cell Division; Epidermal Growth Factor; GPI-Linked Proteins; H | 2003 |
[Activin A-follistatin: new cytokines, new perspectives].
Topics: Activins; Cytokines; Follistatin; Humans; Inhibin-beta Subunits; Kidney Diseases; Neoplasms | 2003 |
Antagonists of activin signaling: mechanisms and potential biological applications.
Topics: Activins; Animals; Cachexia; Hormone Antagonists; Humans; Neoplasms; Signal Transduction; Wound Heal | 2005 |
[TGF-beta family (TGF-beta, activin, BMP)].
Topics: Activins; Apoptosis; Bone Morphogenetic Proteins; Cell Differentiation; DNA-Binding Proteins; Fibros | 2005 |
Activin signaling and its role in regulation of cell proliferation, apoptosis, and carcinogenesis.
Topics: Activin Receptors; Activins; Apoptosis; Cell Differentiation; Cell Proliferation; Follistatin; Human | 2006 |
Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer.
Topics: Activin Receptors; Activins; Animals; Antineoplastic Agents; Bone Morphogenetic Proteins; Drug Deliv | 2008 |
Transgenic models to study the roles of inhibins and activins in reproduction, oncogenesis, and development.
Topics: Activins; Animals; Growth; Inhibins; Mice; Mice, Knockout; Mice, Transgenic; Models, Biological; Neo | 1996 |
Mechanisms of inhibin signal transduction.
Topics: Activin Receptors; Activins; Animals; DNA, Complementary; Female; Follicle Stimulating Hormone; Gene | 2001 |
Activins and inhibins in endocrine and other tumors.
Topics: Activins; Animals; Endocrine Gland Neoplasms; Inhibins; Neoplasms; Signal Transduction; Tumor Suppre | 2001 |
20 other studies available for activins and Benign Neoplasms
| Article | Year |
|---|---|
Targeting activins and inhibins to treat reproductive disorders and cancer cachexia.
Topics: Activins; Animals; Cachexia; Female; Follicle Stimulating Hormone; Humans; Inhibins; Mice; Neoplasms | 2023 |
BRD9-mediated control of the TGF-β/Activin/Nodal pathway regulates self-renewal and differentiation of human embryonic stem cells and progression of cancer cells.
Topics: Activins; Cell Cycle Proteins; Cell Differentiation; Embryonic Stem Cells; Human Embryonic Stem Cell | 2023 |
Generation of reporter cell lines for factors inducing muscle wasting in cancer cachexia.
Topics: Activins; Animals; Cachexia; Cell Line, Transformed; Genes, Reporter; Green Fluorescent Proteins; Hu | 2020 |
Circulating Activin A predicts survival in cancer patients.
Topics: Activins; Adipose Tissue; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Body Composition; Cache | 2017 |
The Dynamics of TGF-β Signaling Are Dictated by Receptor Trafficking via the ESCRT Machinery.
Topics: Activins; Animals; Bone Morphogenetic Proteins; Cell Line; Down-Regulation; Endosomal Sorting Comple | 2018 |
Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors.
Topics: Activins; Aged; Aged, 80 and over; Antineoplastic Agents; Biliary Tract Neoplasms; Biomarkers; C-Rea | 2019 |
ALK7 Signaling Manifests a Homeostatic Tissue Barrier That Is Abrogated during Tumorigenesis and Metastasis.
Topics: Activin Receptors, Type I; Activins; Animals; Apoptosis; Breast Neoplasms; Carcinogenesis; Cell Line | 2019 |
First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors.
Topics: Activins; Antineoplastic Agents; Granulosa Cells; Humans; Maximum Tolerated Dose; Neoplasms; Ovarian | 2019 |
TGFβ-mediated suppression of CD248 in non-cancer cells via canonical Smad-dependent signaling pathways is uncoupled in cancer cells.
Topics: Activins; Animals; Antigens, CD; Antigens, Neoplasm; Bone Morphogenetic Protein 2; Cell Line, Tumor; | 2014 |
Differential Effects of IL6 and Activin A in the Development of Cancer-Associated Cachexia.
Topics: Activins; Animals; Blotting, Western; Cachexia; Disease Models, Animal; Enzyme-Linked Immunosorbent | 2016 |
Baicalin supplementation reduces serum biomarkers of skeletal muscle wasting and may protect against lean body mass reduction in cancer patients: Results from a pilot open-label study.
Topics: Absorptiometry, Photon; Activins; Aged; Biomarkers; Body Weight; Cachexia; Endpoint Determination; F | 2016 |
Activin inhibits telomerase activity in cancer.
Topics: Activins; Down-Regulation; HeLa Cells; Humans; Neoplasms; Recombinant Proteins; Telomerase; Tumor Su | 2009 |
Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGFbeta, Nodal, Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors.
Topics: Activins; Animals; Base Sequence; Comparative Genomic Hybridization; Conserved Sequence; DNA-Binding | 2010 |
Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.
Topics: Activin Receptors, Type II; Activins; Animals; Anorexia; Atrophy; Cachexia; Female; Humans; Inhibins | 2010 |
Cachexia in cancer: is it treatable at the molecular level?
Topics: Activins; Cachexia; Humans; Muscle, Skeletal; Myostatin; Neoplasms; Receptors, Androgen | 2010 |
InACTIVatINg cancer cachexia.
Topics: Activin Receptors, Type II; Activins; Animals; Cachexia; Disease Models, Animal; Humans; Mice; Muscl | 2011 |
TGF-β down under 2011-the experts interviewed!
Topics: Activins; Congresses as Topic; Follistatin; Humans; Inhibins; Neoplasms; Receptors, Transforming Gro | 2011 |
A dormant state modulated by osmotic pressure controls clonogenicity of prostate cancer cells.
Topics: Activins; Animals; Cell Cycle; Cell Line, Tumor; Culture Media, Conditioned; Humans; Male; Mice; Neo | 2011 |
Serum immunoreactive activin A levels in normal subjects and patients with various diseases.
Topics: Activins; Adult; Aged; Aged, 80 and over; Aging; Endocrine System Diseases; Female; Growth Substance | 1996 |
New developments in the biology of inhibins, activins and follistatins.
Topics: Activin Receptors; Activins; Animals; Cell Division; Female; Follistatin; Glycoproteins; Humans; Inf | 2001 |